Rebecca Cottman, PhD, on Enhancing Cell Therapy Cytotoxicity With a Regulated Gene Circuit
The scientist at Senti Biosciences discussed preclinical research presented at ASGCT 2023.
“We validated that all of the ERT2 variants we engineered and put into our transcriptional switches demonstrated maintained insensitivity to estradiol. So we know that it is safe and can be used across a wide range of the population... There's been so many cases in drug development, where I feel like certain populations haven't been considered in the development of that particular therapy. And we're definitely trying to be as inclusive and make sure that this we're designing this to be safe for everyone. And we're excited excited about the potential applications in a host of other primary cells.”
Senti Biosciences is developing a gene circuit using tamoxifen metabolites (endoxifen) that is able to induce robust, controllable expression of interleukin-12 (IL-12) in the brain and other tissues. The research is meant to address the need for enhancing tumor cell cytotoxicity of chimeric antigen receptor (CAR) T-cell therapies without high levels of toxicity that often result with the use of cytokines such as IL-12 alone.
Preclinical, proof-of-concept data were presented by Rebecca Cottman, PhD, scientist, Senti Biosciences, at the American Society of Gene and Cell Therapy (ASGCT) 2023 Annual Meeting, held May 16-20, in Los Angeles, California. CGTLive spoke with Cottman to learn more about the potential advantages of the circuit and the promising sensitivity of its transcriptional switch. She stressed that the research sought to ensure that this method could be accessible to most of the population and validated that the estradiol receptor-based ERT2 small molecule binding domain demonstrated insensitivity to estradiol. She also touched on the potential of combining the gene circuit with other therapies in the future.
Click here to read more coverage of the ASGCT 2023 meeting.
